In phase I clinical trials NMS-P937 was administered orally.

Inhibition of Plk1 kinase activity was assessed using a Dowex resin capture technique. In this assay, 85 μM RCasein (Sigma) was phosphorylated by 3 nM Plk1 (2-345) in the presence of ATP (40 μM) traced with 33P-γ-ATP in kinase buffer (50mMHepes pH=7.9, 10mM beta glycerylphosphate, mMDTT, 3 μMNaVO3, 10 mM MgCl2, 0.2 mg/mL BSA) for min. By addition of an acidic suspension of Dowex resin SIGMA, custom-prepared resin Dowex 1  8200-400 mesh equilibrated in 150 mM sodium formate, pH = 3.0) the unreacted ATP was captured and separated from the supernatant which contained the phosphorylated substrate: this was then transferred into a new plate for radioactivity counting. The assay is run in a robotized format on 384-well plates.